Janney Montgomery Scott reiterated their buy rating on shares of Agile Therapeutics, Inc. (NASDAQ:AGRX) in a research note published on Thursday. They currently have a $13.00 price objective on the specialty pharmaceutical company’s stock.

Several other brokerages have also issued reports on AGRX. Noble Financial reiterated a buy rating on shares of Agile Therapeutics in a report on Sunday, July 30th. HC Wainwright began coverage on Agile Therapeutics in a report on Wednesday, July 19th. They issued a buy rating and a $10.00 price target on the stock. Royal Bank Of Canada set a $8.00 price target on Agile Therapeutics and gave the stock a buy rating in a report on Sunday, July 16th. Finally, ValuEngine upgraded Agile Therapeutics from a strong sell rating to a sell rating in a report on Saturday, July 8th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The stock has an average rating of Buy and a consensus target price of $8.75.

Agile Therapeutics (NASDAQ:AGRX) traded up 3.097% during trading on Thursday, hitting $3.495. The stock had a trading volume of 448,974 shares. Agile Therapeutics has a one year low of $1.82 and a one year high of $7.95. The firm’s market capitalization is $100.68 million. The stock has a 50 day moving average of $3.80 and a 200 day moving average of $3.40.

Agile Therapeutics (NASDAQ:AGRX) last announced its earnings results on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.02. During the same period in the prior year, the business posted ($0.29) EPS. Equities research analysts expect that Agile Therapeutics will post ($1.03) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Agile Therapeutics, Inc. (AGRX) Receives “Buy” Rating from Janney Montgomery Scott” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/09/08/agile-therapeutics-inc-agrx-receives-buy-rating-from-janney-montgomery-scott.html.

In other news, Chairman Alfred Altomari purchased 10,000 shares of the business’s stock in a transaction on Friday, August 25th. The shares were acquired at an average price of $3.34 per share, for a total transaction of $33,400.00. Following the completion of the acquisition, the chairman now owns 161,587 shares in the company, valued at $539,700.58. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 3.50% of the stock is currently owned by corporate insiders.

Several hedge funds have recently bought and sold shares of the company. Royce & Associates LP lifted its holdings in shares of Agile Therapeutics by 1.1% in the second quarter. Royce & Associates LP now owns 998,582 shares of the specialty pharmaceutical company’s stock valued at $3,745,000 after purchasing an additional 11,000 shares in the last quarter. Royal Bank of Canada lifted its holdings in shares of Agile Therapeutics by 608.0% in the second quarter. Royal Bank of Canada now owns 32,497 shares of the specialty pharmaceutical company’s stock valued at $122,000 after purchasing an additional 27,907 shares in the last quarter. Janney Montgomery Scott LLC bought a new position in shares of Agile Therapeutics in the second quarter valued at approximately $122,000. Susquehanna International Group LLP bought a new position in shares of Agile Therapeutics in the second quarter valued at approximately $205,000. Finally, LMR Partners LLP bought a new position in shares of Agile Therapeutics in the second quarter valued at approximately $211,000. Institutional investors own 67.59% of the company’s stock.

About Agile Therapeutics

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Analyst Recommendations for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.